WG
HRMY icon

Winton Group’s Harmony Biosciences HRMY Stock Holding History

Winton Group’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-69,536
Closed -$2.25M – 725
2023
Q4 		$2.25M Buy
69,536
+57,438
+475% +$1.6M 0.16% 101
2023
Q3 		$396K Sell
12,098
-695
-5% -$24.1K 0.03% 367
2023
Q2 		$450K Sell
12,793
-25,590
-67% -$883K 0.04% 371
2023
Q1 		$1.25M Buy
38,383
+16,309
+74% +$743K 0.08% 363
2022
Q4 		$1.22M Buy
22,074
+5,350
+32% +$294K 0.08% 353
2022
Q3 		$741K Buy
16,724
+6,017
+56% +$294K 0.05% 517
2022
Q2 		$522K Buy
+10,707
New +$482K 0.03% 683
2022
Q1 		– Sell
-6,932
Closed -$296K – 1049
2021
Q4 		$296K Buy
+6,932
New +$276K 0.02% 836

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Winton Group's HRMY Position: Q1 2024 in Review

Winton Group sold out of Harmony Biosciences (HRMY) in Q1 2024, closing a stake of 69,536 shares — an estimated $2.25M sold.

Winton Group first reported a position in HRMY in Q4 2021 and held it in 8 quarters. The position peaked at $2.25M in Q4 2023. 208 funds tracked by Wall St. Rank hold HRMY as of Q1 2024.

  • Winton Group reported no remaining Harmony Biosciences position as of Q1 2024 after selling out during the quarter.
  • Winton Group sold 69,536 Harmony Biosciences shares in Q1 2024, an estimated $2.25M.
  • Winton Group first reported a position in Harmony Biosciences in Q4 2021 and held it in 8 quarters.
  • Winton Group's Harmony Biosciences position peaked at $2.25M in Q4 2023.
  • 208 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2024.

Based on Winton Group's 13F filing for Q1 2024, filed 14 May 2024.